세계 세균성 폐렴 시장 – 2023-2030

Overview
The global Bacterial Pneumonia market reached US$ 2.7 billion in 2022 and is expected to reach US$ 5.0 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2023-2030.
The bacterial pneumonia market trends show rising research owing to the rising technological advancements and research studies. Several antibiotics are being launched for the treatment of bacterial pneumonia. Vaccines are also utilized for prevention of bacterial pneumonia in adults as well as pediatrics.
Furthermore, rising treatment for bacterial pneumonia due to the rising availability of approved vaccines or drugs and increase in the number of pneumonia caused by bacteria cases in the market, and an increase in the research and development is driving up the bacterial pneumonia market size.
The market is experiencing a growth in demand for vaccines from North America areas as a result of the rising advancements in this field. With significant competitors like Innoviva Inc., Pfizer Inc., Merck & Co., Inc., and Aridis Pharmaceuticals Inc. actively operating in the market, the market will grow in upcoming time.
Dynamics
The Growing Number of Novel Product Launches Drive the Growth of the Bacterial Pneumonia Market
Bacterial pneumonia is going to see tremendous growth owing to positive safety and efficacy outcomes in clinical trials leading to novel product launches. For instance, on March 14, 2022, the introduction of Cumberland's VIBATIV (telavancin) injectable in Puerto Rico was announced by the specialized pharmaceutical firms Verity Pharmaceuticals International Ltd. and Cumberland Pharmaceuticals Inc.
Following an agreement between the businesses, Verity was given the go-ahead to launch the medicine for patients in the respective market. In people who have hospital-acquired or ventilator-associated pneumonia brought on by diseases like the flu and COVID-19, VIBATIV may be able to save their lives.
An FDA-approved and patented injectable anti-infective is called VIBATIV. It is intended to treat severe infections brought on by Methicillin-sensitive Staphylococcus aureus (MSSA) or Methicillin-resistant Staphylococcus aureus (MRSA), as well as other Gram-positive bacteria. A variety of Gram-positive bacterial infections, among which are difficult to treat and multidrug resistant, are addressed by VIBATIV. The market is predicted to take the lead throughout the forecast period owing to high research studies.
Rising Collaboration by Key Players or Several Organizations Creates Opportunities for the Growth of the Market
As a result of years of study, a number of major manufacturers or governmental/non-governmental organizations are now collaborating for development or study of several novel products for their usage as antibiotics to treat several diseases such as hospital acquired penumonia, which is promoting the expansion of the bacterial pneumonia market.
For instance, on July 10, 2023, a partnership between Melinta Therapeutics, LLC and the Biomedical Advanced Research and Development Authority (BARDA) has been announced to advance two antibiotics that are currently FDA-approved for adults, VABOMERE (meropenem and vaborbactam) and BAXDELA (delafloxacin), for use in pediatrics. Melinta Therapeutics, LLC is a commercial-stage company that develops novel therapies for acute and life-threatening illnesses.
Additionally, Melinta and BARDA will collaborate on the creation of BAXDELA, a drug against diseases that pose a biothreat. BARDA has provided $20.5 million for the base duration of this contract, plus an additional $121.4 million in funding options, for a total investment of up to $141.9 million if each of the options are exercised. Such research collaborations may help in providing better treatments via high study on bacterial pneumonia.
Side Effects Associated with the Treatments will hamper the growth of the market
Patients who received VABOMERE during the clinical trials reported experiencing hypersensitivity responses. Patients getting treatment with beta-lactam antibacterial medications have reported serious and occasionally deadly hypersensitivity reactions as well as serious skin reactions.
There have been cases where people taking another beta-lactam antibacterial medicine developed significant hypersensitivity reactions despite having a history of being hypersensitive to Vaccines. Nearly all antibacterial medications, including VABOMERE, have been linked to Clostridioides difficile-associated diarrhea (CDAD), which can range in severity from moderate diarrhea to deadly colitis.
Since CDAD has been known to occur more than two months following the administration of antimicrobial Treatments, a thorough medical history is required. Meropenem, an ingredient in VABOMERE, has been linked to seizures and other severe reactions involving the central nervous system. These elements can limit the market's expansion.
Segment Analysis
The global bacterial pneumonia market is segmented based type, treatments and distribution channel.
Owing to High Prevalence, the Community-Acquired Pneumonia (CAP) from Type Segment Accounted for Approximately 68.2% of the Bacterial Pneumonia Market Share
The community-acquired pneumonia (CAP) category from type held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of Bacterial Pneumonia worldwide. One of the most prevalent infectious diseases and a significant contributor to global mortality and morbidity is community-acquired pneumonia (CAP).
Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae are examples of common bacterial infections that cause CAP. According to National Institute of Health, the estimated global incidence of community-acquired pneumonia, which is influenced by geography, the season, and population characteristics, ranges from 1.5 to 14 cases per 1000 person-years.
The most common reason for hospitalization, fatality, and high medical expenses is community-acquired pneumonia. Determining the right level of care is crucial for improving results in addition to early detection and appropriate and prompt treatment because disease presentation can range from a mild illness which can be handled as an outpatient to a serious condition that requires treatment in the intensive care unit.
Geographical Penetration
North America Accounted for Approximately 37.1% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Due to the rising need for bacterial pneumonia treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for treatments for bacterial pneumonia.
Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of bacterial infections, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of bacterial pneumonia market share of this region.
It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various treatments and drugs for bacterial pneumonia that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.
Competitive Landscape
The major global players in the bacterial pneumonia market include Innoviva Inc., Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics LLC, Evopoint Biosciences, Aridis Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Eagle Pharmaceuticals, Inc., Clarametyx Biosciences and Basilea Pharmaceutica Ltd among others.
COVID-19 Impact Analysis
Russia Ukraine Conflict Analysis
Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide bacterial pneumonia market. The growth of the global bacterial pneumonia market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.
By Type
• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)
o Ventilator-associated pneumonia (VAP)
o Healthcare-associated pneumonia (HCAP)
By Route of Administration
• Oral
• Subcutaneous
• Others
By Treatments
• Vaccines
o Pneumococcal Conjugate Vaccines
o Pneumococcal Polysaccharide Vaccine
• Drugs
o Fluoroquinolones
 Ciprofloxacin
 Delafloxacin
 Gemifloxacin
 Levofloxacin
o Monobactams
 Azactam
 Aztreonam
o Tetracyclines
 Doxycycline
 Chlortetracycline
 Oxytetracycline
o Macrolides
 Azithromycin
 Clarithromycin
 Erythromycin
o Carbapenems
 Doripenem
 Ertapenem
o Antibiotics
 Lincomycin
 Pirlimycin
 Clindamycin
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On July 27, 2023, Merck released encouraging topline findings from two Phase 3 studies assessing V116, the company's experimental 21-valent pneumococcal conjugate Drugs, in those who had never received a Drugs before and those who had. The first pneumococcal conjugate vaccination created especially for adults, if authorized, would be V116. Results from the STRIDE-3 trial showed that in adults who had never received a Drugs, serotype-specific opsonophagocytic activity (OPA) measured 30 days after vaccination revealed significant immune responses in comparison with PCV20 (pneumococcal 20-valent conjugate Drugs).
• On June 1, 2023, the Phase 3 program, which included the ASSEMBLE (NCT03580044) and REVISIT (NCT03329092) studies evaluating the effectiveness, safety, and acceptability of the newly developed investigational antibiotic aztreonam-avibactam (ATM-AVI) combination in treating severe bacterial infections caused by Gram-negative bacteria, has produced encouraging results, according to Innoviva Inc. Data show that ATM-AVI is safe, efficacious, well-tolerated, and has an identical safety profile to that of aztreonam alone.
• On May 4, 2021, a generic version of Erythromycin Tablets, the reference listed drug (RLD) by Arbor Pharmaceuticals, 250 mg or 500 mg strength generic Erythromycin tablets have been released by Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. The generic Erythromycin pills from Teva are prescribed to treat a range of bacterial illnesses as well as to stop the onset or recurrence of rheumatic fever in those who are penicillin allergic.
Why Purchase the Report?
• To visualize the global bacterial pneumonia market segmentation based on type, route of administration, treatments, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bacterial pneumonia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global bacterial pneumonia market report would provide approximately 53 tables, 54 figures and 195 Pages.
DMI Opinion:
The global bacterial pneumonia market is going to see decent growth in upcoming years owing to rising usage of bacterial pneumonia vaccine and novel product launches. Several researches are taking place worldwide for pneumonia vaccine development. Numerous advances are taking place leading to the growth of market such as novel antibiotics. According to DMI the bacterial pneumonia market will see a decent growth with several novel therapies in the market.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies